Pharmacological (PAG) inhibition of CTH on human glioblastoma cells results to lower Glioblastoma Stem Cell (GSC) formation and lower mRNA expression of stem cell markers (i.e, PROM1, NOX4). This evidence concerns the gene PROM1 and glioblastoma.